CUV103 Singaporean Phase II vitiligo study results

19 December 2018

SUMMARY

• Phase II study in vitiligo, a treatment-resistant disease¹
• n=21, patients of Asian ethnicity, darker skin complexion
• Pooled analysis of data collected on all patients who received SCENESSE^® with NB-UVB (n=18)
• Six doses of SCENESSE^® subcutaneously administered monthly in combination with NB-UVB twice a week
• Repigmentation therapy with SCENESSE^® in combination with NB-UVB effective and safety profile maintained:

– Statistically significant increase in pigmentation on areas of vitiligo for total body, areas of head and neck (VASI, p<0.001 at Day 196), as well hands,       upper extremities, trunk and lower extremities (VASI, p<0.05 at Day 196), with exception of the feet – Maintenance of pigmentation observed at Day 280, three months after the end of the treatment – Combination therapy of SCENESSE^® with NB-UVB well tolerated.